BamSEC and AlphaSense Join Forces
Learn More

Climb Bio Inc. – Material Contracts

NASDAQ: CLYM    
Share price (7/6/26): $13.27    
Market cap (7/6/26): $760 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 63 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 8 pages December 11, 2025 Climb Bio, Inc. 20 William Street, Suite 145 Wellesley Hills, Ma 02481 Re: Section 3(a)(9) Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.1
from 10-Q 25 pages Climb Bio, Inc. 2025 Inducement Plan Adopted by the Board of Directors: March 31, 2025
12/34/56
EX-10.1
from 8-K 13 pages September 30, 2025 Susan Altschuller via Email to [**] Re: Offer of Employment Dear Susan, We Are Very Pleased to Offer You Employment With Climb Bio, Inc. (The “Company”), Effective October 1, 2025 (The “Start Date”). the Initial Terms of Your Employment With the Company Are as Set Forth in This Offer Letter Agreement (The “Agreement”). Position Your Initial Position Will Be Chief Financial Officer, and You Shall Be Responsible for Performing Such Duties as Are Assigned to You From Time to Time Consistent With Duties Typically Associated With That Position, Reporting to the Company’s Chief Executive Officer. Company & Work Location
12/34/56
EX-10.1
from 10-Q 20 pages February 1, 2025 Perrin Wilson via Email to [**] Re: Offer of Employment
12/34/56
EX-10.1
from 8-K 9 pages Separation and Release of Claims Agreement
12/34/56
EX-10.6
from 10-Q 3 pages Climb Bio, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.5
from 10-Q 13 pages Climb Bio, Inc. Rsu Award Grant Notice
12/34/56
EX-10.4
from 10-Q 13 pages Climb Bio, Inc. Stock Option Grant Notice
12/34/56
EX-10.14
from 10-K 91 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Technology Transfer and Exclusive License Agreement by and Between Beijing Mabworks Biotech Co., Ltd. and Climb Bio, Inc
12/34/56
EX-10.4
from 10-K 12 pages Climb Bio, Inc. 2021 Employee Stock Purchase Plan Adopted by the Compensation Committee of the Board of Directors: July 26, 2021 Approved by the Stockholders: July 29, 2021
12/34/56
EX-10.3
from 10-K 13 pages Climb Bio, Inc. Rsu Award Grant Notice
12/34/56
EX-10.2
from 10-K 12 pages Climb Bio, Inc. Stock Option Grant Notice
12/34/56
EX-10.1
from 10-K 24 pages Climb Bio, Inc. 2021 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: July 26, 2021 Approved by the Stockholders: July 29, 2021
12/34/56
EX-10.2
from 10-Q 2 pages Amendment to Consulting Agreement
12/34/56
EX-10.1
from 10-Q 8 pages Eliem Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.1
from 8-K 15 pages Without Prejudice and Subject to Contract Settlement Agreement This Deed Is Made on August 23, 2024
12/34/56
EX-10.1
from 8-K 14 pages July 31, 2024 Brett Kaplan via Email to [**] Re: Employment Terms Dear Brett: Eliem Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment on the Terms and Conditions Set Forth in This Offer Letter Agreement (The “Agreement”) Beginning on August 26, 2024 (The “Start Date”). Position
12/34/56
EX-10.3
from 8-K 28 pages Cell Line Development, Manufacturing Services and License Agreement
12/34/56